Login to Your Account

Financings Roundup

Oncomed Files IPO; Funds to Support CSC-Targeting Drugs

By Catherine Shaffer
Staff Writer

Thursday, May 17, 2012
Oncomed Pharmaceuticals Inc. filed an initial public offering (IPO), hoping for about $115 million to support its antibody therapies targeted at cancer stem cells (CSCs).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription